TransMedics (TMDX) Discloses Aircraft Fleet Acquisitions — Material 10/06/2025

TransMedics (TMDX) Discloses Aircraft Fleet Acquisitions — Material 10/06/2025

Rhea-AI Filing Summary

Insights

FAQ

Q: What did TransMedics (TMDX) disclose in the Form 8-K?

Q: Does the 8-K list purchase price or financing for the aircraft?

Q: Did TransMedics state how many aircraft will be acquired?

Q: Who signed the Form 8-K for TransMedics (TMDX)?

Q: Is the acquisition described as material?

Positive

Negative

8-K Event Classification

What did TransMedics (TMDX) disclose in the Form 8-K?

Does the 8-K list purchase price or financing for the aircraft?

Did TransMedics state how many aircraft will be acquired?

Who signed the Form 8-K for TransMedics (TMDX)?

Is the acquisition described as material?

The company disclosed it considers certain Acquisitions to be a series of related transactions to acquire a fleet of aircraft for use in its National OCS Program and signed the filing on October 6, 2025.

No. The disclosed text contains no purchase price, financing details, or cash impact for the acquisitions.

No. The filing references a fleet of aircraft but does not specify the number or types of aircraft.

The filing is signed by Gerardo Hernandez, identified as Chief Financial Officer and Treasurer.

Yes. The company reported the Acquisitions as a material event on the Form 8-K.

TransMedics Group, Inc. filed a Form 8-K disclosing a material event: the company considers certain Acquisitions to be a series of related transactions to acquire a fleet of aircraft for use in its National OCS Program.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

TransMedics Group, Inc. filed a Form 8-K disclosing a material event: the company considers certain Acquisitions to be a series of related transactions to acquire a fleet of aircraft for use in its National OCS Program. The filing identifies this as a material event and is signed by Gerardo Hernandez, Chief Financial Officer and Treasurer on October 6, 2025. The notice states the purpose of the aircraft is to support the company’s National OCS Program but provides no financial terms, sources of financing, timelines, or specific aircraft counts in the disclosed text.

Strategic capacity expansion: acquisition of a fleet of aircraft to support the National OCS Program
Material disclosure: company reported the transactions as a material event, increasing transparency

No financial terms disclosed: purchase price, financing sources, and impact on cash flows are not provided
No operational details: aircraft count, delivery timeline, and counterparty identities are absent

TL;DR: The company announced aircraft acquisitions for its National OCS Program but provided no financial details.

The statement that the transactions are a "series of related transactions" suggests the acquisitions are connected operationally, likely intended to expand logistics capacity for the National OCS Program. Acquiring a fleet typically affects capital expenditures, balance-sheet commitments, and operating logistics.

Key dependencies and risks include the unreported purchase price, financing method, delivery schedule, and integration costs; each can materially affect cash flow and leverage over the near term. Monitor filings for follow-up disclosures of purchase price, financing structure, delivery dates, and any impact on guidance within the next reporting period.

TL;DR: The 8-K treats the acquisitions as material and related; additional disclosure is likely required if terms change or additional material facts arise.

Labeling the event as material and related signals the company believes investors need timely information. This creates an expectation for subsequent disclosures if material terms (costs, liabilities, covenants) are agreed or modified.

Watch for amendments or subsequent 8-Ks that include concrete terms, contract counterparty names, or financing commitments. Any material change should appear promptly in follow-up SEC filings.

Item 2.01 — Completion of Acquisition or Disposition of Assets

1 item

Item 2.01 Completion of Acquisition or Disposition of Assets Financial

The company completed a significant acquisition or sale of business assets.

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

The company disclosed it considers certain Acquisitions to be a series of related transactions to acquire a fleet of aircraft for use in its National OCS Program and signed the filing on October 6, 2025.

No. The disclosed text contains no purchase price, financing details, or cash impact for the acquisitions.

No. The filing references a fleet of aircraft but does not specify the number or types of aircraft.

The filing is signed by Gerardo Hernandez, identified as Chief Financial Officer and Treasurer.

Yes. The company reported the Acquisitions as a material event on the Form 8-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 10/06/2025 - 04:15 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 3, 2025

TransMedics Group, Inc.

(Exact name of Registrant as Specified in Its Charter)

Massachusetts

001-38891

83-2181531

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

200 Minuteman Road

Andover, Massachusetts

01810

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (978) 552-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange

on which registered

Common Stock, no par value per share

TMDX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.01.

Completion of Acquisition or Disposition of Assets.

As previously disclosed in a Current Report on Form 8-K filed by TransMedics Group, Inc. (the “Company”) on September 5, 2023, a Current Report on Form 8-K filed by the Company on September 12, 2023, a Current Report on Form 8-K filed by the Company on September 22, 2023, a Current Report on Form 8-K filed by the Company on November 13, 2023, a Current Report on Form 8-K filed by the Company on December 19, 2023, a Current Report on Form 8-K filed by the Company on January 2, 2024, a Current Report on Form 8-K filed by the Company on January 29, 2024, a Current Report on Form 8-K filed by the Company on February 6, 2024, a Current Report on Form 8-K filed by the Company on March 12, 2024, a Current Report on Form 8-K filed by the Company on July 2, 2024, a Current Report on Form 8-K filed by the Company on July 29, 2024, a Current Report on Form 8-K filed by the Company on September 11, 2024, a Current Report on Form 8-K filed by the Company on December 9, 2024, a Current Report on Form 8-K filed by the Company on January 14, 2025, and a Current Report on Form 8-K filed by the Company on February 21, 2025 (together, the “Prior Reports”), TransMedics, Inc. (the “Buyer”), a Delaware corporation and wholly-owned subsidiary of the Company, acquired 21 fixed-wing aircraft (collectively, the “Prior Acquisitions”) as more specifically described in the Prior Reports.

Subsequently, on October 3, 2025, the Buyer acquired a fixed-wing aircraft from Teaghlach Aviation, LLC for a purchase price of approximately $14.5 million (together with the Prior Acquisitions, the “Acquisitions”). The Company intends to use each of the 22 aircraft it has acquired to date to transport donor organs as part of the services offered under the Company’s National OCS Program, and for purposes of this Current Report on Form 8-K the Company considers the Acquisitions to be a series of related transactions with respect to the acquisition of a fleet of aircraft for use in the Company’s National OCS Program.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

TRANSMEDICS GROUP, INC.

Date: October 6, 2025

/s/ Gerardo Hernandez

Gerardo Hernandez

Chief Financial Officer and Treasurer